Literature DB >> 20447482

Immunofluorescence mapping for the diagnosis of epidermolysis bullosa.

Gabriela Pohla-Gubo1, Rodrigo Cepeda-Valdes, Helmut Hintner.   

Abstract

Immunofluorescence mapping is based on the detection of structural proteins of keratinocytes or of the dermo-epidermal junction using specific poly- or monoclonal antibodies. Through this method, the level of split formation can be determined by investigating the location of a given antigen in a natural or induced blister. This method also allows testing for the normal expression, reduction or absence of various structural proteins depending on the antibodies used. It has widely replaced transmission electron microscopy and is used as the initial laboratory test to prove the clinical diagnosis of epidermolysis bullosa. Copyright 2010 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20447482     DOI: 10.1016/j.det.2009.12.005

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  4 in total

Review 1.  [Practical aspects of molecular diagnostics in genodermatoses].

Authors:  C Has; Y He
Journal:  Hautarzt       Date:  2016-01       Impact factor: 0.751

2.  Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa.

Authors:  Marilina Tampoia; Domenico Bonamonte; Angela Filoni; Lucrezia Garofalo; Maria Grazia Morgese; Luigia Brunetti; Chiara Di Giorgio; Giuseppina Annicchiarico
Journal:  Orphanet J Rare Dis       Date:  2013-09-04       Impact factor: 4.123

3.  Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa.

Authors:  C Has; L Liu; M C Bolling; A V Charlesworth; M El Hachem; M J Escámez; I Fuentes; S Büchel; R Hiremagalore; G Pohla-Gubo; P C van den Akker; K Wertheim-Tysarowska; G Zambruno
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

4.  Utility of Immunofluorescence Antigen Mapping in Hereditary Epidermolysis Bullosa.

Authors:  Raghavendra Rao; Varsha M Shetty
Journal:  Indian J Dermatol       Date:  2021 Jul-Aug       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.